Drug news
CHMP recommends Eylea for treatment of Diabetic Macular Edema- Regeneron + Bayer
Regeneron Pharmaceuticals, Inc. announced that Eylea(aflibercept) Injection has been recommended for approval by the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of visual impairment due to Diabetic Macular Edema (DME). The decision of the European Commission is expected in the second half of 2014. The European Union (EU) submission is based on positive data from the Phase III VIVID-DME and VISTA-DME studies.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.